← Back to Search

Genomic Tumor Board Review for Cancer

N/A

Recruiting

Led By Jens Rueter

Research Sponsored by Southwest Oncology Group

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up baseline and month 27 after study activation

Awards & highlights

No Placebo-Only Group

Summary

This trialcompares the usual approach to cancer treatment with an enhanced approach that includes a team of experts to review and suggest treatment options based on genomic test results.

Who is the study for?

This trial is for adults with stage III or IV solid tumors that are recurrent, relapsed, refractory, metastatic, or newly diagnosed and advanced. Participants must be under the care of a study-enrolled physician and have genomic tumor tests ordered but not yet received results. They should not be on hospice care and must consent to participate.

What is being tested?

The trial examines if an educationally enhanced genomic tumor board (EGTB) can increase genome-informed treatment in patients with serious solid tumors. It compares usual review methods of genomic test results against those reviewed by a GTB—a team experienced in interpreting genetic changes—to improve treatment decisions.

What are the potential side effects?

Since this trial focuses on educational interventions rather than direct medical treatments, traditional side effects associated with medications are not applicable here. However, there may be indirect effects from any new treatments chosen as a result of the GTB's recommendations.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ baseline and month 27 after study activation

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~baseline and month 27 after study activation

This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline and month 27 after study activation for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.

Primary study objectives

Therapeutic procedure

Secondary study objectives

Overall survival

Overall survival on new anticancer therapy

Physician experience using genomic tumor testing (GTT) in practice

+3 more

Awards & Highlights

No Placebo-Only Group

All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups

Experimental Treatment

Active Control

Group I: Arm 2 (EGTB)Experimental Treatment6 Interventions

Patients and physicians receive the EGTB intervention. This is comprised of 2 components: the structured GTB and the supporting education. Physicians submit cases for discussion to the GTB within 2 weeks of GTT results. The GTB sessions are held weekly and conducted virtually over a video-conferencing platform. Each case presentation is 10 to 15 minutes long, and 4 to 6 cases are discussed during each 60 minute GTB session. GTT results and clinical data are presented and expert interpretation of genomic test results is provided to help prioritize potential treatment options and provide a framework for interpretation. Supporting education materials are also available online to participants to support GTT decision making.

Group II: Arm 1 (usual care)Active Control5 Interventions

Participants receive usual care. This consists of physicians ordering GTT for patients and reviewing the results without the GTB being involved.

Do I qualify?Apply below to find out